Get notified when OFIX files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Securities Litigation (worsened) — The securities class action advanced with a partial dismissal and an amended complaint, keeping the litigation active.
NASDAQ: OFIX Orthofix Medical Inc. 10-Q

Orthofix sales rise 3.8% to $210.9M, but net loss widens 12.2% on non-operating items

Filed August 5, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 5, 2025 · ~1 min read

Key Changes

  • high

    Net loss widened 12.2% to $15.8M despite a 49% narrower operating loss, as non-operating/other items swung -$8.6M and income tax -$943,000.

    MD&A: Operating loss verify on EDGAR →
  • high

    Free cash flow deteriorated to -$47.1M from -$20.6M on higher capex and working capital, even as operating results improved.

    MD&A: Free cash flow verify on EDGAR →
  • high

    Company drew the full $65M Term B Loan in January 2026, lifting total term debt to $225M and increasing leverage.

    Notes: Long-term debt draw view on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (ESTC 10-Q) is open in full — no account needed.

Partner

Trade OFIX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify